Kelly Alberda, MD
Family Medicine · Austin, TXNPI 1972525376
Payments from drug & device makers
Across 276 payments — averaging $26.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$3K
- Novo Nordisk$963
- AbbVie$627
- AstraZeneca$405
- Abbott$314
- Lilly USA, LLC$290
- plus $2K from 29 others
What the payments were for
- Speaking & faculty fees$2,75038%
- Food & beverage$4,49062%
- Education$501%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 6 | $2,805 |
| Novo Nordisk | 72 | $963 |
| AbbVie(2 entities) | 43 | $627 |
| AstraZeneca | 24 | $405 |
| Abbott | 19 | $314 |
| Lilly USA, LLC | 17 | $290 |
| Boehringer Ingelheim | 11 | $288 |
| Pfizer | 15 | $283 |
| Bayer | 6 | $213 |
| GSK | 6 | $89 |
| Amarin Pharma, Inc. | 5 | $84 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $80 |
| Exact Sciences | 4 | $74 |
| Amgen(2 entities) | 5 | $72 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 4 | $66 |
| Sanofi Pasteur Inc. | 3 | $66 |
| Currax Pharmaceuticals LLC | 3 | $66 |
| Amneal Pharmaceuticals LLC | 3 | $63 |
| Gilead | 2 | $47 |
| Idorsia Pharmaceuticals US Inc | 2 | $39 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $38 |
| Viiv Healthcare Company | 2 | $38 |
| Biohaven Pharmaceuticals, Inc. | 2 | $38 |
| Astellas Pharma US Inc | 2 | $32 |
| Exeltis, USA Inc. | 2 | $29 |
| Johnson & Johnson | 2 | $24 |
| Axsome Therapeutics, Inc. | 1 | $22 |
| Otsuka America Pharmaceutical, Inc. | 1 | $21 |
| IBSA Pharma Inc. | 1 | $20 |
| Genentech USA, Inc. | 1 | $18 |
| Clarus Therapeutics Inc. | 1 | $17 |
| Corcept Therapeutics | 1 | $16 |
| Bolton Medical Inc | 1 | $15 |
| Kowa Pharmaceuticals America, Inc. | 1 | $14 |
| Aytu Biopharma, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$7,290 in reported general payments places this provider in the 90th percentile of 8,760 family medicine providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 67 | $94,875 |
| TrulicityDulaglutide | 38 | $50,392 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 37 | $47,955 |
| MounjaroTirzepatide | 38 | $43,949 |
| FarxigaDapagliflozin Propanediol | 25 | $36,584 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 42 | $35,609 |
| JardianceEmpagliflozin | 29 | $34,461 |
| Xigduo XrDapaglifloz Propaned/Metformin | 28 | $31,503 |
| Repatha SureclickEvolocumab | 18 | $19,573 |
| EliquisApixaban | 12 | $11,147 |
| DuleraMometasone/Formoterol | 17 | $7,657 |
| Breo ElliptaFluticasone/Vilanterol | 11 | $5,352 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 16 | $5,002 |
| Atorvastatin Calcium | 473 | $4,975 |
| Icosapent Ethyl | 13 | $3,790 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $963 | $94,87567 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $290 | $94,34276 claims |
| Boehringer IngelheimSynjardy Xr, Jardiance | $288 | $82,41666 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $89 | $40,96253 claims |
| AstraZenecaFarxiga | $405 | $36,58425 claims |
| PfizerEliquis, Levoxyl | $283 | $12,91740 claims |
| MerckDulera | $2,805 | $7,65717 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $63 | $2,385177 claims |
| AbbVieSynthroid | $627 | $2,02443 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 8,760 family medicine providers in Texas.
Other family medicine in Austin
- Cynthia BrinsonAustin$13.9M
- Gregg LucksingerAustin$11.4M
- Faith HolmesAustin$7.5M
- Gretchen CrookAustin$4.4M
- Matthew BrimberryAustin$3.8M
- Nomita KimAustin$3.3M
- Douglas DenhamSan Antonio$68.5M
- Vicki MillerPasadena$58.3M
- Hareshkumar BogharaDesoto$30.3M
- Earl MartinTomball$30.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.